CTOs on the Move

La Casa Assisted Living

www.lacasaassistedliving.com

 
La Casa Assisted Living is a Merritt Island, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 10K-50K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Anokion

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company`s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion`s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.

Applied Proteomics

Applied Proteomics Inc. is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems.

CollabRx

CollabRx is a clinical decision-support company delivering expert solutions in precision oncology that enable physicians, laboratories, payers, and providers to achieve standardized, evidence-based care and superior clinical outcomes. CollabRx uses information technology to aggregate and contextualize the world`s knowledge on genomics-based medicine with specific insights from the nation`s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.

Formycon

Formycon ist ein führender und unabhängiger Entwickler von qualitativ hochwertigen biopharmazeutischen Nachfolgeprodukten, sogenannten Biosimilars.

Civetta Therapeutics

Civetta Therapeutics was founded by William Sellers (Broad Institute and Dana-Farber Cancer Institute) and Eric Fischer (Dana Farber Cancer Institute and Harvard Medical School) to advance new medicines through small molecule intervention targeting propeller domains with the goal of developing important therapeutics for cancer and other indications.